Clinical Trial Update: Trial to Compare the Efficacy and Safety of Pegfilgrastim Biosimilar in Subjects With High Risk Stage Breast Cancer Receiving Chemotherapy [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating a pegfilgrastim biosimilar in high-risk breast cancer patients receiving chemotherapy has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pegfilgrastim biosimilar (pegfilgrastim biosimilar)

Snippet

Sponsor: Eurofarma Laboratorios S.A. | Conditions: Breast Cancer | Phase 3 | Status: WITHDRAWN